Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Head & Neck 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 7Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Mesothelioma 2Melanoma 2Cholangiocarcinoma 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1Anophthalmia with pulmonary hypoplasia 1

Interventions

pembrolizumab 39Gemcitabine 30Nivolumab 15Cetuximab 13Carboplatin 13Cyclophosphamide 12Cisplatin 12Irinotecan 10Docetaxel 10130-nm albumin-bound paclitaxel 10Trastuzumab 8Magnetic Resonance Spectroscopy 8fludarabine 7aldesleukin 7Paclitaxel 7Drug Therapy 7Bevacizumab 7Taxes 6Specimen Handling 6Fluorouracil 6Capecitabine 6Albumin-Bound Paclitaxel 6sargramostim 5Pemetrexed 5Oxaliplatin 5Ipilimumab 5spartalizumab 4durvalumab 4Standard of Care 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × budigalimab × Thoracic × Clear all
NCT05005403 2026-05-13

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AbbVie

Phase 1 Recruiting
694 enrolled
BreastGastrointestinalHead & NeckThoracic

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Trishula Therapeutics, Inc.

Phase 1 Completed
185 enrolled 28 charts
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡